Corporate Profile
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using the company’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels.
The company’s first compound, STK-001 is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease.
The company is pursuing treatment for a second haploinsufficient disease, autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke’s initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting the company’s belief in the broad potential for its proprietary approach.
Press Releases
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
April 17, 2024
– Mr. Hoitt brings more than two decades of successful commercial experience with an emphasis on rare diseases – BEDFORD, Mas ...Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 4, 2024
BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 4, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t ...Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
March 27, 2024
BEDFORD, Mass. --(BUSINESS WIRE)--Mar. 27, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated ...Corporate Presentation
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines.
